John Pomann, MD
Dermatology · Clinton Twp, MINPI 1114933843
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 597 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,133, 7.0 times the $735 reported in 2019. Among dermatology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 597 payments — averaging $36.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$3K
- UCB, Inc.$2K
- Sun Pharmaceutical Industries Inc.$1K
- Zerigo Health, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $9K from 31 others
What the payments were for
- Consulting fees$1,3506%
- Food & beverage$19,57790%
- Education$7644%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 109 | $3,315 |
| Johnson & Johnson | 79 | $3,049 |
| UCB, Inc. | 41 | $1,700 |
| Sun Pharmaceutical Industries Inc. | 32 | $1,486 |
| Zerigo Health, Inc. | 1 | $1,350 |
| Regeneron Healthcare Solutions, Inc. | 29 | $1,312 |
| Sanofi | 33 | $1,178 |
| Incyte Corporation | 20 | $1,052 |
| LEO Pharma Inc. | 27 | $949 |
| Lilly USA, LLC | 29 | $907 |
| Novartis | 52 | $887 |
| E.r. Squibb & Sons, L.L.C. | 28 | $802 |
| Galderma Laboratories, L.p. | 11 | $606 |
| Pfizer | 15 | $484 |
| Arcutis Biotherapeutics, Inc. | 19 | $458 |
| Amgen | 11 | $361 |
| Dermavant Sciences, Inc. | 13 | $285 |
| Organon | 9 | $204 |
| Janssen Scientific Affairs, LLC | 2 | $179 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 9 | $173 |
| VYNE Pharmaceuticals Inc. | 2 | $153 |
| GSK | 1 | $125 |
| AstraZeneca | 1 | $111 |
| Prugen, Inc. Pharmaceuticals | 1 | $110 |
| Almirall LLC | 5 | $85 |
| Fresenius Kabi USA, LLC | 3 | $84 |
| Boehringer Ingelheim | 3 | $52 |
| Mylan Institutional Inc. | 2 | $46 |
| Genentech USA, Inc. | 2 | $38 |
| Convatec Inc. | 1 | $26 |
| Cipher Pharmaceuticals US LLC | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Krystal Biotech Inc | 1 | $21 |
| Verrica Pharmaceuticals Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $11 |
| Biofrontera Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,691 in reported general payments places this provider in the 90th percentile of 404 dermatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 15 | $305,762 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $94,390 |
| Humira(Cf) PenAdalimumab | 11 | $72,828 |
| Taltz AutoinjectorIxekizumab | 11 | $70,291 |
| OtezlaApremilast | 15 | $67,997 |
| AdbryTralokinumab-Ldrm | 14 | $55,884 |
| Fluorouracil | 230 | $14,058 |
| Calcipotriene | 33 | $5,947 |
| Fluocinolone Acetonide | 63 | $2,197 |
| Clobetasol Propionate | 56 | $2,003 |
| Tacrolimus | 18 | $1,916 |
| Pimecrolimus | 12 | $1,890 |
| Desonide | 63 | $1,815 |
| Betamethasone Dipropionate | 35 | $1,688 |
| Roflumilast | 18 | $1,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $361 | $67,99715 claims |
| LEO Pharma Inc.Adbry | $949 | $55,88414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 dermatology providers in Michigan.
Other dermatology in Clinton Twp
- Linda Stein GoldWest Bloomfield$3.3M
- Kristi HawleyCaledonia$2.2M
- David AltmanWarren$1.9M
- Michael SiegelWaterford$708K
- Johann GudjonssonAnn Arbor$535K
- Michael DormanWest Bloomfield$433K
- Steven DaveluyDearborn$350K
- Benjamin WorkmanMidland$284K
- Diana WestgateKalamazoo$252K
- Christofer BuattiAuburn Hills$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.